X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Douglas Petersen

Douglas Petersen Douglas Petersen is PhRMA’s deputy vice president for international trade. Previously, he was international trade counsel for the U.S. Senate Committee on Finance, an international trade attorney with White & Case LLP and a trade policy analyst at the Cato Institute. He received a law degree from New York University, a graduate degree from the London School of Economics, and undergraduate degrees from the University of Utah.

Recent Posts

Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth

By Douglas Petersen  |    May 18, 2023
May is World Trade Month — an opportunity to remind the Biden Administration of the importance of international trade. America’s biopharmaceutical industry, and the hundreds of thousands of Americans...   Read More

Will the administration capitalize on the Indo-Pacific Economic Framework to drive medical innovation?

By Douglas Petersen  |    March 13, 2023
In December 2022, the United States launched negotiations for the Indo-Pacific Economic Framework (IPEF) with thirteen countries throughout the Indo-Pacific region, including Australia, India,...   Read More

Biden administration should prioritize innovation in U.S.-Taiwan Initiative on 21st-Century Trade

By Douglas Petersen  |    January 17, 2023
Last summer, the United States and Taiwan launched the U.S.-Taiwan Initiative on 21st-Century Trade to deepen economic and trade relations. In detailed comments to the U.S. Trade Representative...   Read More

PhRMA submission to USTR calls for urgent defense of American innovation abroad

By Douglas Petersen  |    November 1, 2022
The United States leads the world in medicine research, development and manufacturing, and international trade delivers those medicines to patients around the globe. But trade barriers imposed in...   Read More

PhRMA encourages Biden administration to pursue ambitious Indo-Pacific Economic Framework

By Douglas Petersen  |    April 13, 2022
Last fall, President Biden announced that the United States would explore development of an Indo-Pacific Economic Framework (IPEF) to deepen economic relations in the region and collaborate to...   Read More

PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19 and other diseases

By Douglas Petersen  |    October 29, 2021
The biopharmaceutical industry has been working tirelessly to develop and manufacture innovative vaccines, therapies and diagnostics to combat COVID-19 and other diseases and illnesses. As of October...   Read More

Strengthening the WTOs global trade and health agenda

By Douglas Petersen  |    October 18, 2021
The World Trade Organization (WTO) should use the weeks ahead to focus on delivering an ambitious and productive trade and health agenda as it prepares for the Twelfth Ministerial Conference (MC12)...   Read More

U.S. trade policy must prioritize American biopharmaceutical innovation and patient access

By Douglas Petersen  |    November 2, 2020
As the United States biopharmaceutical industry works around the clock to develop vaccines and treatments for COVID-19, it’s more important than ever that international trade policies facilitate...   Read More

PhRMA submission to 2020 National Trade Estimate Report: Urgent action required to protect U.S. biopharmaceutical innovation

By Douglas Petersen  |    November 8, 2019
International trade policy plays a critical role in ensuring that the U.S. biopharmaceutical industry can continue to develop and provide both American and international patients with access to...   Read More

World Trade Month: How we can expand world-class pro-innovation standards

By Douglas Petersen  |    May 22, 2019
May is World Trade Month—a celebration of the industries that import and export goods and services around the world. The month offers a good opportunity to examine the significance of international...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."